madman
Super Moderator
Optum Rx removes reauthorizations from an additional 40 drugs | Managed Healthcare Executive
Beginning in January 2026, Optum Rx is removing reauthorizations for two new drug classes: hormone therapies and knee osteoarthritis injectables.
Beginning in January 2026, Optum Rx is removing reauthorizations for two new drug classes: hormone therapies and knee osteoarthritis injectables.
Beginning Jan. 1, 2026, Optum Rx, the pharmacy benefit manager of UnitedHealthcare, will reduce reauthorizations for an additional 40 drugs. This expands on the PBM’s efforts earlier this year, and there are now 180 medications with reduced reauthorization requirements.
This effort builds on United Healthcare’s commitment made in March 2025 to make prescription drugs more accessible. In today’s announcement, Optum Rx is eliminating reauthorization on hormone therapies and those for knee authorization.
The additional drug that no longer need reauthorization include:
- Hormone Therapy: Aveed inj, Azmiro inj, Depo-Testosterone inj, Testosterone cypionate inj, Testone inj, Testopel implant pellets, Testosterone implant pellets, Testosterone enanthate inj, Xyosted inj, Jatenzo capsules, Kyzatrex capsules, Methitest tablets, Methyltestosterone capsules, Tlando capsules, Androgel, Natesto, Fortesta gel, Testim gel, Vogelxo gel, Testosterone gel, Testosterone solution
